Trial Profile
A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary) ; Vocimagene amiretrorepvec-flucytosine gene therapy (Primary) ; Vocimagene amiretrorepvec-flucytosine gene therapy (Primary) ; Vocimagene amiretrorepvec-flucytosine gene therapy (Primary)
- Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Solid tumours
- Focus Pharmacodynamics
- Acronyms Toca 6
- Sponsors Tocagen
- 25 Jan 2020 Results (n=17) evaluating Immune modulation after Toca 511 and Toca FC treatment of heavily pretreated colorectal cancer patients, presented at the 2020 Gastrointestinal Cancers Symposium
- 03 Jan 2020 Status changed from active, no longer recruiting to discontinued.
- 08 Nov 2019 Results published in the Tocagen Media Release.